Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials

BACKGROUND: Large-scale vaccination against COVID-19 is being implemented in many countries with CoronaVac, an inactivated vaccine. We aimed to assess the immune persistence of a two-dose schedule of CoronaVac, and the immunogenicity and safety of a third dose of CoronaVac, in healthy adults aged 18...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Gang, Wu, Qianhui, Pan, Hongxing, Li, Minjie, Yang, Juan, Wang, Lin, Wu, Zhiwei, Jiang, Deyu, Deng, Xiaowei, Chu, Kai, Zheng, Wen, Wang, Lei, Lu, Wanying, Han, Bihua, Zhao, Yuliang, Zhu, Fengcai, Yu, Hongjie, Yin, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651254/
https://www.ncbi.nlm.nih.gov/pubmed/34890537
http://dx.doi.org/10.1016/S1473-3099(21)00681-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8651254/
https://www.ncbi.nlm.nih.gov/pubmed/34890537
http://dx.doi.org/10.1016/S1473-3099(21)00681-2

Ejemplares similares